DGAP-News: Neovacs S.A. / Key word(s): Joint Venture
Neovacs and Stellar Biotechnologies sign a joint venture agreement to create
Neostell SAS
12.05.2016 / 08:00
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
PRESS RELEASE
Neovacs and Stellar Biotechnologies sign joint venture agreement to create
Neostell SAS
Paris and Boston, May 12th, 2016 - Neovacs (Alternext Paris: ALNEV) a
leader in active immunotherapy for the treatment of autoimmune diseases,
today announced that the Company has finalized the terms of its partnership
with US company Stellar Biotechnologies Inc. ("Stellar") (Nasdaq: SBOT), to
determine the creation of the production company Neostell SAS under a form
of a joint venture, based in the Paris area and owned 70% by Neovacs and
30% by Stellar Biotechnologies.
Under the terms of this joint venture agreement, Neovacs and Stellar
Biotechnologies have agreed to combine their skills, to manufacture and
sell all types of conjugated vaccines to third party customers worldwide,
as well as produce all of Neovacs' Kinoids, including IFNα-Kinoid.
Investments for this production unit will start after the results of the
Phase IIb study of IFNα-Kinoid in lupus conducted by Neovacs and currently
ongoing. Beyond the interest of 30 % held by Stellar Biotechnologies,
Neovacs has received EUR 5 million for this project from the public funding
program "PIAVE" set up by Bpifrance.
Miguel Sieler, Chief Executive Officer of Neovacs said: "This joint venture
with Stellar Biotechnologies is an important alliance because it further
strengthens Neovacs' industrial plan. Neovacs has secured funding to move
forward on the manufacturing facility and now this joint venture provides
access to a scalable capacity of KLH which is a key component of our Kinoid
technology. These steps will support the manufacturing infrastructure as we
progress through clinical trials and to potential market launch of our KLH-
Kinoid immunotherapy vaccines."
"This partnership is both a natural extension of Stellar's strong
relationship with Neovacs and, we believe, a unique opportunity for
Stellar. It will position Stellar to benefit from the anticipated
manufacturing and sale of finished immunotherapy products and to advance
the market for our KLH protein products," stated Frank Oakes, President,
CEO and Chairman of Stellar Biotechnologies, Inc. "Through this joint
venture, Stellar and Neovacs can work together to ensure the success of
Neovacs' products like IFNα-Kinoid for lupus while we lay the groundwork to
offer similar support to other companies developing KLH-based
immunotherapies."
About Stellar Biotechnologies, Inc.
Stellar Biotechnologies, Inc. (Nasdaq: SBOT) is the leader in sustainable
manufacture of Keyhole Limpet Hemocyanin (KLH), an important immune-
stimulating protein used in wide-ranging therapeutic and diagnostic
markets. KLH is both an active pharmaceutical ingredient (API) in many new
immunotherapies (targeting cancer, immune disorders, Alzheimer's and
inflammatory diseases) as well as a finished product for measuring immune
status. Stellar Biotechnologies is unique in its proprietary methods,
facilities, and KLH technology. We are committed to meeting the growing
demand for commercial-scale supplies of GMP grade KLH, ensuring
environmentally sound KLH production, and developing KLH-based active
immunotherapies.
About Neovacs
Created in 1993, Neovacs is today a leading biotechnology company focused
on an active immunotherapy technology platform (Kinoids) with applications
in autoimmune and/or inflammatory diseases. On the basis of the company's
proprietary technology for inducing a polyclonal immune response (covered
by five patent families that potentially run until 2032) Neovacs is
focusing its clinical development efforts on IFNα-Kinoid, an immunotherapy
being developed for the indication of lupus and dermatomyositis. Neovacs is
also conducting preclinical development works on other therapeutic vaccines
in the fields of auto-immune diseases, oncology and allergies. The goal of
the Kinoid approach is to enable patients to have access to safe treatments
with efficacy that is sustained in these life-long diseases. www.neovacs.fr
Contacts
NEOVACS - Corporate Communication & Investor Relations
Charlène Masson
+33 (0)1 53 10 93 14
cmasson@neovacs.com
Investor Relations / Financial Communications Germany - MC Services
Raimund Gabriel
+49-89-21-02-28-30
raimund.gabriel@mc-services.eu
Press / U.S. Inquiries - The Ruth Group
Lee Roth / Joseph Green
+1-646-536-7012 / 7013
lroth@theruthgroup.com / jgreen@theruthgroup.com
---------------------------------------------------------------------------
12.05.2016 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Neovacs S.A.
3-5, Impasse Reille
75014 Paris
France
Phone: +33 (0)1 53 10 93 00
Fax: +33 (0)1 53 10 93 03
E-mail: www.neovacs.fr
Internet: info@neovacs.fr
ISIN: FR0004032746
WKN: A1CVKR
Listed: Regulated Unofficial Market in Stuttgart; Open Market in
Frankfurt
End of News DGAP News Service
---------------------------------------------------------------------------
462721 12.05.2016
DGAP-News: Neovacs and Stellar Biotechnologies sign a joint venture agreement to create Neostell SAS
| Source: EQS Group AG